Mitoxantrone Ebewe Pharma (Mitoxantrone)

Mitoxantrone intercalates into DNA and locks the topoisomerase II enzyme in a complex that cannot re‑seal DNA strands. This results in persistent double‑strand breaks, halting DNA replication and triggering programmed cell death in rapidly dividing cancer cells.

The dose of Mitoxantrone is individualized by the prescribing oncologist based on factors such as the specific cancer type, disease stage, patient weight, renal and hepatic function, and prior exposure to cardiotoxic agents. No standard dosing can be provided without a medical assessment.

The pregnancy category for Mitoxantrone is unknown, and animal data suggest potential fetal harm. It is generally avoided in pregnant or nursing women unless the potential benefit outweighs the risk. Women of child‑bearing potential should use effective contraception during treatment.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and necessary import documentation.

Mitoxantrone belongs to the anthracenedone subclass, sharing DNA‑intercalating and topoisomerase II‑inhibiting properties with anthracyclines such as doxorubicin. Compared with classic anthracyclines, Mitoxantrone generally shows lower cardiotoxicity at equivalent doses but retains potent antitumor activity, making it a useful alternative in patients with prior anthracycline exposure.

Mitoxantrone Ebewe Pharma should be stored at 2‑8 °C (refrigerated). Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking the solution. Do not store at room temperature for extended periods.

Mitoxantrone is supplied as an injectable solution for intravenous infusion. The infusion is typically given over a period of several minutes to an hour, depending on the prescribed protocol, and is performed under the supervision of qualified healthcare professionals in a clinical setting.

The most serious adverse effects include dose‑related cardiotoxicity, the possible development of secondary acute leukemia, and severe infections resulting from profound neutropenia. Regular cardiac monitoring and blood‑count assessments are essential to detect these risks early.

Mitoxantrone is contraindicated in patients with known hypersensitivity to the drug, those with severe uncontrolled cardiac disease, and individuals with significant hepatic impairment where dose adjustment is not feasible. Caution is also advised for patients who have recently received high‑dose anthracyclines.